

MannKind Corporation

MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Incorporated in 1991, the company is committed to the development of innovative products that address significant unmet medical needs.

- Location:** MannKind's corporate headquarters are located in Valencia, CA. Clinical research and development, regulatory affairs and commercial operations are based in Paramus, NJ. Technical operations and manufacturing are located in Danbury, CT.
- Investor Overview:** MannKind trades on the NASDAQ under the ticker symbol MNKD. As of October 7, 2010, MannKind had 113,760,000 shares outstanding and the Company had a market cap of \$750.82M.
- Product Pipeline:** AFREZZA[®] (insulin human [rDNA origin]) is an ultra rapid-acting mealtime insulin therapy in late stage clinical investigation for the treatment of adult patients with Type 1 and Type 2 diabetes mellitus for the control of hyperglycemia. It is a drug-device combination product, consisting of AFREZZA Inhalation Powder pre-metered into single use unit-dose cartridges and the light, discreet and easy-to-use AFREZZA Inhaler. AFREZZA utilizes the company's proprietary Technosphere[®] formulation technology.

MKC253

MKC253 is a Technosphere formulation of GLP-1 (glucagon-like peptide). In initial clinical studies, MKC253 showed a lack of the characteristic adverse events, like nausea and vomiting, that are frequently associated with long-acting GLP-1 analogs. Results from a phase 1 trial support the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with Type 2 diabetes.

MKC180

MKC180 is a novel Technosphere formulation of a natural hormone to control satiety for addressing obesity. The product is an inhaled oxyntomodulin intended for use at mealtime. In nonclinical studies, MKC180 demonstrated a dose dependent decrease in food consumption up to six hours after pulmonary administration and was superior to both placebo and an IV infusion of oxyntomodulin.

MKC1106

MKC1106 is MannKind's active immunotherapy platform, and there are three separate programs. MKC1106-PP, designed to target solid tumors, completed an open label phase 1 clinical trial and objective responses were observed in prostate cancer and renal cell carcinoma. MKC1106-MT, specific for melanoma treatment, also showed objective responses in a Phase 1 clinical trial. MKC1106-NS may be applicable to a range of solid and blood cancers and is positioned for clinical evaluation.

MKC204

MKC204 is an IRE-1 alpha inhibitor with potential application in the treatment of multiple myeloma. IRE-1 alpha is a protein important in the regulation of the Unfolded Protein Response (UPR) cascade. Additional potential indications for UPR pathway inhibitors include autoimmune diseases, cardiovascular diseases and neurodegenerative disorders.

**Technosphere
Technology:**

MannKind's proprietary Technosphere[®] Technology platform is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. The technology enables rapid systemic delivery of a broad range of therapeutics agents, including proteins, peptides and small molecule drugs via oral inhalation to the deep lung utilizing MannKind's proprietary inhalers. In addition to the compounds highlighted previously, MannKind currently has a variety of Technosphere formulations in development to treat conditions such as osteoporosis, hypoglycemia, migraine and pain associated with irritable bowel syndrome.